Miao Yingying, Liang Yamei, Zhang Zhe, Cai Benben
Department of Pediatrics, The First People's Hospital of Taizhou City, Taizhou, China.
Medicine (Baltimore). 2025 Mar 21;104(12):e41371. doi: 10.1097/MD.0000000000041371.
This study investigates the therapeutic effect of montelukast sodium combined with budesonide in children with cough variant asthma (CVA) and its influence on the levels of forced expiratory volume in one second (FEV1) and forced vital capacity (FVC). A total of 112 children with CVA treated in our hospital from January 2019 to January 2021 were selected. According to the different treatment methods, they were divided into control group and experimental group, and the clinical data of each group were collected retrospectively. The control group was treated with budesonide, and the study group was treated with Montelukast sodium combined with budesonide. The clinical therapeutic effect, lung function level, adverse reactions and inflammatory factors were compared between the 2 groups. The effective rate in the study group was 92.9%, compared to 73.2% in the control group, with the study group showing significantly higher rates (P < .05). There was no significant difference in pulmonary function index levels between the 2 groups before drug intervention (P > .05), but levels of all indexes improved after treatment. The levels of FEV1, FVC, peak expiratory flow, and FEV1/FVC in the study group were higher than those in the control group (P < .05). The incidence of adverse reactions such as nausea, rash, and headache was 25.0% in the study group and 23.2% in the control group, with no significant difference between the 2 groups (P > .05). Before treatment, there was no significant difference in the levels of inflammatory factors between the 2 groups (P > .05). After treatment, levels of TNF-α, IL-6, and IgE improved in both groups, with the study group showing lower levels than the control group (P < .05). Montelukast sodium combined with budesonide in the treatment of children with CVA enhances the treatment effect, improves pulmonary function, inhibits inflammatory factors, and does not increase adverse drug reactions, making it a valuable treatment option.
本研究探讨孟鲁司特钠联合布地奈德治疗咳嗽变异性哮喘（CVA）患儿的疗效及其对一秒用力呼气容积（FEV1）和用力肺活量（FVC）水平的影响。选取2019年1月至2021年1月在我院治疗的112例CVA患儿。根据治疗方法不同，将其分为对照组和试验组，并回顾性收集每组的临床资料。对照组采用布地奈德治疗，研究组采用孟鲁司特钠联合布地奈德治疗。比较两组的临床治疗效果、肺功能水平、不良反应及炎症因子。研究组有效率为92.9%，对照组为73.2%，研究组有效率显著更高（P<0.05）。药物干预前两组肺功能指标水平无显著差异（P>0.05），但治疗后所有指标水平均有所改善。研究组的FEV1、FVC、呼气峰流速和FEV1/FVC水平高于对照组（P<0.05）。研究组恶心、皮疹、头痛等不良反应发生率为25.0%，对照组为23.2%，两组间无显著差异（P>0.05）。治疗前两组炎症因子水平无显著差异（P>0.05）。治疗后，两组的TNF-α、IL-6和IgE水平均有所改善，研究组水平低于对照组（P<0.05）。孟鲁司特钠联合布地奈德治疗CVA患儿可提高治疗效果，改善肺功能，抑制炎症因子，且不增加药物不良反应，是一种有价值的治疗选择。
